Apollomics Inc. Announces $2.0 Million Bridge Financing
MWN-AI** Summary
Apollomics Inc. (Nasdaq: APLM), a clinical-stage biopharmaceutical company focused on oncology therapies, recently announced a $2.0 million bridge financing arrangement in the form of an unsecured Convertible Promissory Note with its Chairman and CEO, Mr. Hung-Wen (Howard) Chen. This financing, finalized on March 30, 2026, aims to provide necessary working capital to support the company’s clinical programs and general operations. Notably, the Note carries a 0% interest rate and will automatically convert into equity securities upon the completion of a subsequent equity financing that raises at least $10.0 million, with a conversion price set at a 20% discount to the lowest per-share price offered to new investors in that round.
This related-party transaction received prior approval from both the independent Audit Committee and the Board of Directors, excluding Mr. Chen from the voting process. The decision followed a thorough evaluation of financing options and benchmarking against current market conditions in the biotechnology sector.
Apollomics specializes in developing innovative cancer therapies, with its lead program, vebreltinib (APL-101), targeting non-small cell lung cancer and other advanced tumors with c-Met alterations. This therapy is currently undergoing a Phase 2 clinical trial across the United States and over 10 other countries.
The company cautioned investors about potential risks associated with its forward-looking statements, which may relate to operational oversight, regulatory environment, clinical trial outcomes, and other uncertainties. As Apollomics positions itself for future developments, the financing is set to play a critical role in advancing its oncology portfolio. For more information, visit www.apollomicsinc.com.
MWN-AI** Analysis
Apollomics Inc. (Nasdaq: APLM) has recently announced a $2.0 million bridge financing arrangement with its Chairman and CEO, Mr. Hung-Wen (Howard) Chen. This financing, positioned as an unsecured Convertible Promissory Note, is geared towards bolstering the company’s working capital to support its clinical development programs and general operations. Investors should approach this development with a balanced view of opportunity and caution.
On one hand, the provision of working capital through this financing indicates Apollomics's commitment to advancing its clinical programs, particularly its lead candidate, vebreltinib (APL-101), a selective c-Met inhibitor currently in clinical trials for non-small cell lung cancer. The company's efforts to secure funding through a related-party transaction, reviewed by an independent audit committee, suggests a level of corporate governance that could reassure investors regarding the integrity of the financing process.
However, potential investors should also consider the risks outlined in the company’s cautionary statements. The unsecured nature of the Note, carrying a 0% interest rate, positions this as a higher-risk investment when compared to traditional loans. Furthermore, the automatic conversion to equity upon subsequent financing introduces dilution concerns for existing shareholders, especially since the conversion price is tied to a 20% discount to future financing rounds, which may affect the valuation of current shares.
In summary, while the bridge financing can provide essential liquidity and signals a proactive approach to funding, investors should remain wary of potential regulatory hurdles, uncertainties in clinical development outcomes, and the overall volatility of the biotech sector. Conducting thorough due diligence is essential before making investment decisions in Apollomics, particularly in light of upcoming performance metrics from its clinical trials or any new regulatory developments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible Promissory Note (the “Note”) with Mr. Hung-Wen (Howard) Chen, the Company’s Chairman and Chief Executive Officer, on March 30, 2026.
The $2.0 million in proceeds from the Note are intended to provide the Company with necessary working capital to support clinical development programs and general corporate operations.
The Note is an unsecured obligation of the Company and carries a 0% interest rate. Under the terms of the agreement, the principal amount will automatically convert into equity securities of the Company upon the closing of a subsequent equity financing with aggregate gross proceeds of at least $10.0 million. The conversion price will be calculated at a 20% discount to the lowest per-share price issued to investors in such financing.
The terms of the related-party transaction were reviewed and approved by the Company’s independent Audit Committee and the Board of Directors, with Mr. Chen abstaining from the vote. The transaction followed a comprehensive evaluation of the Company’s financing alternatives and a benchmarking analysis against current market terms for similar bridge financing transactions in the biotechnology sector.
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and over 10 other countries. For more information, please visit www.apollomicsinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives, including with respect to the anticipated use of proceeds from the Note, the potential conversion of the Note into equity securities, and the Company's future financing plans, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.
These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Apollomics cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of Apollomics. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including: (i) the impact of any current or new government regulations in the United States and China affecting Apollomics’ operations and the continued listing of Apollomics’ securities; (ii) the inability to achieve successful clinical results or to obtain licensing of third-party intellectual property rights for future discovery and development of Apollomics’ oncology projects; (iii) the failure to commercialize product candidates and achieve market acceptance of such product candidates; (iv) the failure to protect Apollomics’ intellectual property; (v) breaches in data security; (vi) the risk that Apollomics may not be able to develop and maintain effective internal controls; (vii) unfavorable changes to the regulatory environment; and (viii) those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2024 (filed with the SEC on April 3, 2025) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, except to the extent required by applicable law.
Investor Contacts:Peter Lin, Chief Financial OfficerApollomics, Inc.1-650-209-4055peter.lin@apollomicsinc.com
FAQ**
How will the $2.0 million raised through the unsecured Convertible Promissory Note contribute to the advancement of Apollomics Inc. Warrant APLMW, especially concerning the company's ongoing clinical trials?
With the automatic conversion of the Note into equity upon a future financing initiative, what potential impact does this have on existing shareholders of Apollomics Inc. Warrant APLMW?
Considering the detailed risk factors outlined in the press release, what strategic measures is Apollomics implementing to mitigate potential threats to its operations and those affecting the Apollomics Inc. Warrant APLMW?
How does the 20% discount on the conversion price in the Convertible Promissory Note reflect Apollomics Inc.’s current valuation and prospects for investors holding Apollomics Inc. Warrant APLMW?
**MWN-AI FAQ is based on asking OpenAI questions about Apollomics Inc. (NASDAQ: APLM).
NASDAQ: APLM
APLM Trading
0.66% G/L:
$13.80 Last:
16,999 Volume:
$14.79 Open:
